CO2020000369A2 - Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos - Google Patents
Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismosInfo
- Publication number
- CO2020000369A2 CO2020000369A2 CONC2020/0000369A CO2020000369A CO2020000369A2 CO 2020000369 A2 CO2020000369 A2 CO 2020000369A2 CO 2020000369 A CO2020000369 A CO 2020000369A CO 2020000369 A2 CO2020000369 A2 CO 2020000369A2
- Authority
- CO
- Colombia
- Prior art keywords
- fusion proteins
- modified polypeptides
- polypeptides
- serum albumin
- complement component
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531215P | 2017-07-11 | 2017-07-11 | |
| PCT/US2018/041661 WO2019014360A1 (en) | 2017-07-11 | 2018-07-11 | POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020000369A2 true CO2020000369A2 (es) | 2020-01-31 |
Family
ID=63036501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0000369A CO2020000369A2 (es) | 2017-07-11 | 2020-01-15 | Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11498960B2 (https=) |
| EP (1) | EP3625265A1 (https=) |
| JP (3) | JP7684803B2 (https=) |
| KR (3) | KR102806328B1 (https=) |
| CN (3) | CN111201246B (https=) |
| AU (3) | AU2018301412B2 (https=) |
| BR (1) | BR112019028269A2 (https=) |
| CA (1) | CA3067247A1 (https=) |
| CO (1) | CO2020000369A2 (https=) |
| IL (3) | IL307197B2 (https=) |
| MX (2) | MX2024005945A (https=) |
| WO (1) | WO2019014360A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102806328B1 (ko) | 2017-07-11 | 2025-05-14 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질 |
| US20210388070A1 (en) * | 2018-10-30 | 2021-12-16 | Alexion Pharmaceuticals, Inc. | Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions |
| EP3956344A1 (en) * | 2019-04-16 | 2022-02-23 | University of Washington | Amantadine binding protein |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| BR112022010742A2 (pt) | 2019-12-26 | 2022-08-16 | Eisai R&D Man Co Ltd | Composição farmacêutica contendo ácido ribonucleico de fita dupla que inibe a expressão de c5 complementar |
| JP7343618B2 (ja) | 2020-01-17 | 2023-09-12 | オリンパス株式会社 | 発光装置、および駆動装置 |
| EP4135837A1 (en) | 2020-04-16 | 2023-02-22 | Assistance Publique, Hopitaux De Paris | Methods for treating a complement mediated disorder caused by viruses |
| IL301713A (en) * | 2020-10-05 | 2023-05-01 | Alexion Pharma Inc | Methods for treating dermatomyositis |
| CN120018862A (zh) * | 2022-08-31 | 2025-05-16 | 阿雷克森制药公司 | 用于治疗镰状细胞病的融合多肽的剂量和施用 |
| CN116731149B (zh) * | 2023-06-07 | 2024-02-27 | 华中农业大学 | 草鱼补体活化分子碳末端肽C5a-CP及应用 |
| CN119241699B (zh) * | 2024-09-24 | 2025-11-28 | 广州康盛生物科技股份有限公司 | 一种抗人补体c5的单域抗体及其应用 |
| CN121518561A (zh) * | 2025-12-24 | 2026-02-13 | 北京林业大学 | 一种PagRAP2.3蛋白点突变及其在植物愈伤再生中的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| ES2294799T3 (es) | 1996-06-27 | 2008-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana. |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| EP1240337B1 (en) | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US7083784B2 (en) * | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| AU2002335930B2 (en) | 2001-03-09 | 2005-07-28 | Morphosys Ag | Serum albumin binding moieties |
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| WO2004041863A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
| EP1558645B1 (en) * | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン．ヴェー． | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
| AU2012254935B2 (en) * | 2004-02-12 | 2014-05-29 | Archemix Llc | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders |
| TW200607523A (en) * | 2004-06-01 | 2006-03-01 | Domantis Ltd | Drug compositions, fusions and conjugates |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| CN100368022C (zh) | 2005-09-20 | 2008-02-13 | 中国人民解放军第二军医大学 | 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法 |
| US7807409B2 (en) * | 2005-10-21 | 2010-10-05 | Roche Palo Alto Llc | Method for the recombinant expression of a polypeptide |
| SG10201804008UA (en) | 2005-11-04 | 2018-06-28 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| DK2262831T3 (en) | 2008-03-03 | 2015-04-27 | Novelmed Therapeutics Inc | ANTI-Properdin ANTIBODIES |
| PY09026846A (es) * | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| CA2766565A1 (en) * | 2009-06-23 | 2010-12-29 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| WO2011064382A1 (en) | 2009-11-30 | 2011-06-03 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| EP2531523A1 (en) * | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| CA2811221C (en) | 2010-03-10 | 2018-01-09 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-properdin antibodies |
| TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| CN103003296A (zh) | 2010-07-09 | 2013-03-27 | 阿菲博迪公司 | 多肽 |
| TW201241008A (en) | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| KR20140064768A (ko) | 2011-07-01 | 2014-05-28 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 항-프로퍼딘 항체 및 그의 용도 |
| ES2728278T3 (es) | 2011-12-21 | 2019-10-23 | Novartis Ag | Composiciones que comprenden anticuerpos dirigidos al factor P y C5 |
| WO2013102123A2 (en) | 2011-12-28 | 2013-07-04 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
| EP3511339B1 (en) | 2012-02-20 | 2025-04-09 | IPC Research, LLC | Polypeptides binding to human complement c5 |
| CA2887050A1 (en) | 2012-10-04 | 2014-04-10 | Novelmed Therapeutics, Inc. | Alternative pathway specific antibodies for treating hemolytic diseases |
| BR112016003142A2 (pt) | 2013-08-28 | 2017-10-17 | Swedish Orphan Biovitrum Ab Publ | ligação de polipeptídeos estáveis ao c5 do complemento humano |
| MX367423B (es) | 2013-08-28 | 2019-08-21 | Affibody Ab | Polipeptidos de union a c5. |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| MX2019008827A (es) | 2017-01-30 | 2019-09-26 | Alexion Pharma Inc | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. |
| KR102806328B1 (ko) | 2017-07-11 | 2025-05-14 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질 |
-
2018
- 2018-07-11 KR KR1020207002889A patent/KR102806328B1/ko active Active
- 2018-07-11 CN CN201880046102.3A patent/CN111201246B/zh active Active
- 2018-07-11 EP EP18746529.9A patent/EP3625265A1/en active Pending
- 2018-07-11 IL IL307197A patent/IL307197B2/en unknown
- 2018-07-11 JP JP2020500686A patent/JP7684803B2/ja active Active
- 2018-07-11 CA CA3067247A patent/CA3067247A1/en active Pending
- 2018-07-11 AU AU2018301412A patent/AU2018301412B2/en active Active
- 2018-07-11 BR BR112019028269-6A patent/BR112019028269A2/pt unknown
- 2018-07-11 KR KR1020257014994A patent/KR20250068795A/ko active Pending
- 2018-07-11 KR KR1020257021037A patent/KR20250099285A/ko active Pending
- 2018-07-11 CN CN202311281093.5A patent/CN117327187A/zh active Pending
- 2018-07-11 US US16/629,687 patent/US11498960B2/en active Active
- 2018-07-11 WO PCT/US2018/041661 patent/WO2019014360A1/en not_active Ceased
- 2018-07-11 CN CN202311281139.3A patent/CN117327188A/zh active Pending
- 2018-07-11 IL IL271920A patent/IL271920B2/en unknown
-
2020
- 2020-01-08 MX MX2024005945A patent/MX2024005945A/es unknown
- 2020-01-08 MX MX2024005946A patent/MX2024005946A/es unknown
- 2020-01-15 CO CONC2020/0000369A patent/CO2020000369A2/es unknown
-
2022
- 2022-10-07 US US17/938,756 patent/US12221473B2/en active Active
-
2023
- 2023-05-24 JP JP2023085796A patent/JP2023120208A/ja active Pending
-
2025
- 2025-01-02 US US19/007,782 patent/US20250163138A1/en active Pending
- 2025-01-16 AU AU2025200303A patent/AU2025200303A1/en active Pending
- 2025-01-16 AU AU2025200313A patent/AU2025200313A1/en active Pending
- 2025-03-18 JP JP2025044077A patent/JP2025118590A/ja active Pending
- 2025-10-21 IL IL324119A patent/IL324119A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020000369A2 (es) | Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos | |
| CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
| CL2018002694A1 (es) | Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112) | |
| CL2018003136A1 (es) | Proteínas de unión específica y usos de las mismas. | |
| CY1124834T1 (el) | Αναστολεις της αλληλεπιδρασης της μηνινης-mll | |
| CL2021000516A1 (es) | Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| CO2018003852A2 (es) | Proteínas de unión a antigeno que activan el receptor de leptina | |
| CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
| AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
| MX2018009581A (es) | Inmunoglobulina con fabs en tandem y sus usos. | |
| CO2018003863A2 (es) | Anticuerpos anti-vegf | |
| BR112019010265A2 (pt) | anticorpos anti_cd137 inovadores e usos dos mesmos | |
| BR112016015140A2 (pt) | imunoglobulina com fabs in-tandem e usos das mesmas | |
| CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
| AR100215A1 (es) | Conjugados de anticuerpo-fármaco anti-ptk7 | |
| CL2018003438A1 (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos. | |
| EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
| BR122020006914B8 (pt) | Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado | |
| AR095596A1 (es) | Moléculas de unión de cadena única comprendiendo n-terminal abp | |
| UY36561A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| MX2019014448A (es) | Inmunoglobulinas de enlace a mmp13. | |
| BR112019010034A2 (pt) | fator viii alvejado de hemácia e método de uso do mesmo | |
| BR112017024714A2 (pt) | métodos para preparação do fator de von willebrand modificado |